MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 620 participants.
Also called NCT03961334
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 620 participants
- Registry
-
NCT03961334
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Greece, Norway, Spain, Switzerland, United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT03961334. Randomized; no masking; primary purpose prevention. Start 2019-12-05 (actual); primary completion 2025-01-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Acronym
- MOSES
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- Dabigatran
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- University of Zurich
- Collaborator
- Swiss National Science Foundation
Record details
- Record id
cardio:ct-nct03961334- Content hash
a3d272fbbbe91f105dd8fdec20db1ef62da4d928a0efc3ef73818d8d1a036952